Etanercept improves psoriatic arthritis patient-reported outcomes : Results from EDUCATE
Experience Diagnosing, Understanding Care, and Treatment With Etanercept (EDUCATE) is a multicenter, phase 4, 24-week, open-label study of the safety and efficacy of etanercept therapy in patients with psoriatic arthritis (PsA) in routine dermatologic practice. We present data on patient-reported ou...
Gespeichert in:
| Veröffentlicht in: | Cutis (New York, N.Y.) N.Y.), 2007-04, Vol.79 (4), p.322-326 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 326 |
|---|---|
| container_issue | 4 |
| container_start_page | 322 |
| container_title | Cutis (New York, N.Y.) |
| container_volume | 79 |
| creator | FRANKEL, Ellen H STROBER, Bruce E CROWLEY, Jeffrey J FIVENSON, David P WOOLLEY, J. Michael YU, Elaine B XIA, Hong A CHIOU, Chiun-Fang STEVENS, Seth R |
| description | Experience Diagnosing, Understanding Care, and Treatment With Etanercept (EDUCATE) is a multicenter, phase 4, 24-week, open-label study of the safety and efficacy of etanercept therapy in patients with psoriatic arthritis (PsA) in routine dermatologic practice. We present data on patient-reported outcomes (PROs) from EDUCATE, which demonstrate that subjects with PsA achieved clinically meaningful improvements in both skin- and joint-related PROs after 24 weeks of treatment. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70493244</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70493244</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-5fd2f4f6922ff5cd9e8eee4f79b3cbd95ea031cf7b3b5696a4acc853b0446fa13</originalsourceid><addsrcrecordid>eNpF0E1LxDAQBuAgiruu_gXJRW-FfLVpvC1r_YAFQXbBW0nTCUbaTU1SwX9vwBVPwzs8DDNzgpaMs6qoFFOnaEkIpYWgFVugixg_clRMynO0oLIkhNd0id6apA8QDEwJu3EK_gsinqIPTidnsA7pPbjkci9nOKQiwORDgh77ORk_Zn2HXyHOQ4rYBj_i5n6_We-aS3Rm9RDh6lhXaP_Q7DZPxfbl8Xmz3hYT4yoVpe2ZFTYvzKwtTa-gBgBhpeq46XpVgiacGis73pWVqrTQxtQl74gQldWUr9Dt79y8--cMMbWjiwaGIZ_l59hKIhRnQmR4fYRzN0LfTsGNOny3f7_I4OYIdDR6sEEfjIv_rpZMUKb4D-JSals</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70493244</pqid></control><display><type>article</type><title>Etanercept improves psoriatic arthritis patient-reported outcomes : Results from EDUCATE</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>FRANKEL, Ellen H ; STROBER, Bruce E ; CROWLEY, Jeffrey J ; FIVENSON, David P ; WOOLLEY, J. Michael ; YU, Elaine B ; XIA, Hong A ; CHIOU, Chiun-Fang ; STEVENS, Seth R</creator><creatorcontrib>FRANKEL, Ellen H ; STROBER, Bruce E ; CROWLEY, Jeffrey J ; FIVENSON, David P ; WOOLLEY, J. Michael ; YU, Elaine B ; XIA, Hong A ; CHIOU, Chiun-Fang ; STEVENS, Seth R</creatorcontrib><description>Experience Diagnosing, Understanding Care, and Treatment With Etanercept (EDUCATE) is a multicenter, phase 4, 24-week, open-label study of the safety and efficacy of etanercept therapy in patients with psoriatic arthritis (PsA) in routine dermatologic practice. We present data on patient-reported outcomes (PROs) from EDUCATE, which demonstrate that subjects with PsA achieved clinically meaningful improvements in both skin- and joint-related PROs after 24 weeks of treatment.</description><identifier>ISSN: 0011-4162</identifier><identifier>EISSN: 2326-6929</identifier><identifier>PMID: 17500381</identifier><identifier>CODEN: CUTIBC</identifier><language>eng</language><publisher>Chatham, NJ: Quadrant HealthCom</publisher><subject>Arthritis, Psoriatic - drug therapy ; Biological and medical sciences ; Dermatology ; Diseases of the osteoarticular system ; Etanercept ; Female ; Health Status ; Humans ; Immunoglobulin G - therapeutic use ; Immunologic Factors - therapeutic use ; Inflammatory joint diseases ; Male ; Medical sciences ; Middle Aged ; Psoriasis. Parapsoriasis. Lichen ; Quality of Life ; Randomized Controlled Trials as Topic ; Receptors, Tumor Necrosis Factor - therapeutic use ; Recombinant Fusion Proteins - therapeutic use ; Treatment Outcome</subject><ispartof>Cutis (New York, N.Y.), 2007-04, Vol.79 (4), p.322-326</ispartof><rights>2007 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18724129$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17500381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FRANKEL, Ellen H</creatorcontrib><creatorcontrib>STROBER, Bruce E</creatorcontrib><creatorcontrib>CROWLEY, Jeffrey J</creatorcontrib><creatorcontrib>FIVENSON, David P</creatorcontrib><creatorcontrib>WOOLLEY, J. Michael</creatorcontrib><creatorcontrib>YU, Elaine B</creatorcontrib><creatorcontrib>XIA, Hong A</creatorcontrib><creatorcontrib>CHIOU, Chiun-Fang</creatorcontrib><creatorcontrib>STEVENS, Seth R</creatorcontrib><title>Etanercept improves psoriatic arthritis patient-reported outcomes : Results from EDUCATE</title><title>Cutis (New York, N.Y.)</title><addtitle>Cutis</addtitle><description>Experience Diagnosing, Understanding Care, and Treatment With Etanercept (EDUCATE) is a multicenter, phase 4, 24-week, open-label study of the safety and efficacy of etanercept therapy in patients with psoriatic arthritis (PsA) in routine dermatologic practice. We present data on patient-reported outcomes (PROs) from EDUCATE, which demonstrate that subjects with PsA achieved clinically meaningful improvements in both skin- and joint-related PROs after 24 weeks of treatment.</description><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Dermatology</subject><subject>Diseases of the osteoarticular system</subject><subject>Etanercept</subject><subject>Female</subject><subject>Health Status</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Inflammatory joint diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>Quality of Life</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0011-4162</issn><issn>2326-6929</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1LxDAQBuAgiruu_gXJRW-FfLVpvC1r_YAFQXbBW0nTCUbaTU1SwX9vwBVPwzs8DDNzgpaMs6qoFFOnaEkIpYWgFVugixg_clRMynO0oLIkhNd0id6apA8QDEwJu3EK_gsinqIPTidnsA7pPbjkci9nOKQiwORDgh77ORk_Zn2HXyHOQ4rYBj_i5n6_We-aS3Rm9RDh6lhXaP_Q7DZPxfbl8Xmz3hYT4yoVpe2ZFTYvzKwtTa-gBgBhpeq46XpVgiacGis73pWVqrTQxtQl74gQldWUr9Dt79y8--cMMbWjiwaGIZ_l59hKIhRnQmR4fYRzN0LfTsGNOny3f7_I4OYIdDR6sEEfjIv_rpZMUKb4D-JSals</recordid><startdate>20070401</startdate><enddate>20070401</enddate><creator>FRANKEL, Ellen H</creator><creator>STROBER, Bruce E</creator><creator>CROWLEY, Jeffrey J</creator><creator>FIVENSON, David P</creator><creator>WOOLLEY, J. Michael</creator><creator>YU, Elaine B</creator><creator>XIA, Hong A</creator><creator>CHIOU, Chiun-Fang</creator><creator>STEVENS, Seth R</creator><general>Quadrant HealthCom</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20070401</creationdate><title>Etanercept improves psoriatic arthritis patient-reported outcomes : Results from EDUCATE</title><author>FRANKEL, Ellen H ; STROBER, Bruce E ; CROWLEY, Jeffrey J ; FIVENSON, David P ; WOOLLEY, J. Michael ; YU, Elaine B ; XIA, Hong A ; CHIOU, Chiun-Fang ; STEVENS, Seth R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-5fd2f4f6922ff5cd9e8eee4f79b3cbd95ea031cf7b3b5696a4acc853b0446fa13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Dermatology</topic><topic>Diseases of the osteoarticular system</topic><topic>Etanercept</topic><topic>Female</topic><topic>Health Status</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Inflammatory joint diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>Quality of Life</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>FRANKEL, Ellen H</creatorcontrib><creatorcontrib>STROBER, Bruce E</creatorcontrib><creatorcontrib>CROWLEY, Jeffrey J</creatorcontrib><creatorcontrib>FIVENSON, David P</creatorcontrib><creatorcontrib>WOOLLEY, J. Michael</creatorcontrib><creatorcontrib>YU, Elaine B</creatorcontrib><creatorcontrib>XIA, Hong A</creatorcontrib><creatorcontrib>CHIOU, Chiun-Fang</creatorcontrib><creatorcontrib>STEVENS, Seth R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cutis (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FRANKEL, Ellen H</au><au>STROBER, Bruce E</au><au>CROWLEY, Jeffrey J</au><au>FIVENSON, David P</au><au>WOOLLEY, J. Michael</au><au>YU, Elaine B</au><au>XIA, Hong A</au><au>CHIOU, Chiun-Fang</au><au>STEVENS, Seth R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Etanercept improves psoriatic arthritis patient-reported outcomes : Results from EDUCATE</atitle><jtitle>Cutis (New York, N.Y.)</jtitle><addtitle>Cutis</addtitle><date>2007-04-01</date><risdate>2007</risdate><volume>79</volume><issue>4</issue><spage>322</spage><epage>326</epage><pages>322-326</pages><issn>0011-4162</issn><eissn>2326-6929</eissn><coden>CUTIBC</coden><abstract>Experience Diagnosing, Understanding Care, and Treatment With Etanercept (EDUCATE) is a multicenter, phase 4, 24-week, open-label study of the safety and efficacy of etanercept therapy in patients with psoriatic arthritis (PsA) in routine dermatologic practice. We present data on patient-reported outcomes (PROs) from EDUCATE, which demonstrate that subjects with PsA achieved clinically meaningful improvements in both skin- and joint-related PROs after 24 weeks of treatment.</abstract><cop>Chatham, NJ</cop><pub>Quadrant HealthCom</pub><pmid>17500381</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0011-4162 |
| ispartof | Cutis (New York, N.Y.), 2007-04, Vol.79 (4), p.322-326 |
| issn | 0011-4162 2326-6929 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70493244 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Arthritis, Psoriatic - drug therapy Biological and medical sciences Dermatology Diseases of the osteoarticular system Etanercept Female Health Status Humans Immunoglobulin G - therapeutic use Immunologic Factors - therapeutic use Inflammatory joint diseases Male Medical sciences Middle Aged Psoriasis. Parapsoriasis. Lichen Quality of Life Randomized Controlled Trials as Topic Receptors, Tumor Necrosis Factor - therapeutic use Recombinant Fusion Proteins - therapeutic use Treatment Outcome |
| title | Etanercept improves psoriatic arthritis patient-reported outcomes : Results from EDUCATE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A29%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Etanercept%20improves%20psoriatic%20arthritis%20patient-reported%20outcomes%20:%20Results%20from%20EDUCATE&rft.jtitle=Cutis%20(New%20York,%20N.Y.)&rft.au=FRANKEL,%20Ellen%20H&rft.date=2007-04-01&rft.volume=79&rft.issue=4&rft.spage=322&rft.epage=326&rft.pages=322-326&rft.issn=0011-4162&rft.eissn=2326-6929&rft.coden=CUTIBC&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70493244%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70493244&rft_id=info:pmid/17500381&rfr_iscdi=true |